Company Filing History:
Years Active: 2014-2015
Title: Innovations of José Manuel Bartolome-Nebreda
Introduction
José Manuel Bartolome-Nebreda is a notable inventor based in Toledo, Spain. He has made significant contributions to the field of pharmacology, particularly in the development of compounds that target neurological and psychiatric disorders. With a total of 2 patents, his work focuses on allosteric modulation of specific glutamate receptors.
Latest Patents
His latest patents include "Substituted 6-methylnicotinamides as mGluR5 positive allosteric modulators." This invention relates to substituted 6-methylnicotinamide analogs and derivatives that serve as positive allosteric modulators of the metabotropic glutamate receptor subtype 5 (mGluR5). The patent also covers synthetic methods for creating these compounds, pharmaceutical compositions that include them, and methods for treating neurological and psychiatric disorders associated with glutamate dysfunction.
Another significant patent is "Substituted pyrazolo[1,5-A]pyrazine compounds as allosteric modulators of mGluR5 receptors." This invention similarly focuses on substituted pyrazolo[1,5-a]pyrazine compounds and their derivatives, which are useful as positive allosteric modulators of mGluR5. It also includes synthetic methods for producing these compounds and their applications in treating related disorders.
Career Highlights
José Manuel Bartolome-Nebreda is affiliated with Vanderbilt University, where he continues to advance research in pharmacology and drug development. His work has been instrumental in exploring new therapeutic avenues for conditions linked to glutamate dysfunction.
Collaborations
He has collaborated with esteemed colleagues such as P Jeffrey Conn and Craig William Lindsley, contributing to a rich environment of innovation and research.
Conclusion
José Manuel Bartolome-Nebreda's contributions to the field of pharmacology through his patents and collaborations highlight his commitment to addressing complex neurological and psychiatric disorders. His innovative work continues to pave the way for future advancements in treatment options.